Delivery Order SPE2DB25D3005-SPE2DB25FQFYE
- Not listed
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. The contract, awarded on September 23, 2025, with an ultimate completion date of October 15, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical product for pulmonary fibrosis treatment. This competitive award was issued on June 20, 2025, with a completion date of July 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating it was awarded through open competition....
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $17,129.75 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment primarily used for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, which was competitively awarded without set-aside provisions, is scheduled for completion by September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a contract ceiling value of $3,425.95. This non-set-aside, competitively awarded delivery order carries firm fixed pricing and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count supply) on July 7, 2025, with an ultimate completion date of July 28, 2025. This is a competitively awarded, firm fixed-price contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pulmonary fibrosis medication. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical will be delivered to the contractor's location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Esbriet 267 mg tablets (270 count) under a firm fixed-price contract valued at $20,555.70, with an ultimate completion date of October 17, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical distributor within the federal medical supply chain. The order will be...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Esbriet 801 mg tablets (90-count) with a completion date of October 6, 2025. This is a firm fixed price, non-set-aside contract performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB25FQFYEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical product for pulmonary fibrosis treatment. This non-competitive, firm fixed-price delivery order was awarded on June 12, 2025, with an ultimate completion date of July 7, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical supply transaction under AmerisourceBergen's larger federal contract portfolio. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies across multiple therapeutic domains to support military and veteran healthcare systems. The prime IDC serves as a global pharmaceutical support vehicle enabling flexible fulfillment of medical procurement needs for the Defense Health Agency and other federal healthcare systems, with the company demonstrating consistent capability to meet federal requirements through competitive federal procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 6/12/25 |